Company profile: 4D Pharma
1.1 - Company Overview
Company description
- Provider of live biotherapeutics, a novel class of drugs defined by the FDA as biological products containing a live organism, such as bacteria, applicable to the prevention, treatment or cure of disease; developer of MicroRx, a proprietary platform.
Products and services
🔒
Key contacts
🔒
🔒
Financial details
🔒
1.2 - Competitors and similar companies to 4D Pharma
MicuRx Pharmaceuticals
HQ: United States
Website
- Description: Provider of novel antimicrobials for drug-resistant infections. Portfolio includes Contezolid (MRX-I), an oxazolidinone for complicated skin and soft tissue infections (targets MRSA, VRE); Contezolid acefosamil (MRX-4), an injectable oxazolidinone in Phase III; MRX-8, a polymyxin for multidrug-resistant Gram-negative; MRX-5, a boron compound; MRX-7, a pleuromutilin inhibitor; and MRX-15, a kidney-targeted therapy.
- Rationale: This competitor operates in a highly similar market segment with overlapping features.
- Company type: Private company
- Employees: ●●●●●
- Total funding raised: $●●●m
- Backers: ●●●●●●●●●●
- Acquisitions: ●●
View full MicuRx Pharmaceuticals company profile →
Adaptive Phage Therapeutics
HQ: United States
Website
- Description: Provider of phage-based therapeutic services for multi-drug resistant pathogenic bacteria, using clinical technology to match phages to patient-specific infections; offerings include BX004 for cystic fibrosis Pseudomonas aeruginosa, BX211 for diabetic foot osteomyelitis, personalized and optimized phage therapies, and the XMarker platform for microbial biomarker discovery.
- Rationale: This competitor operates in a highly similar market segment with overlapping features.
- Company type: Private company
- Employees: ●●●●●
- Total funding raised: $●●●m
- Backers: ●●●●●●●●●●
- Acquisitions: ●●
View full Adaptive Phage Therapeutics company profile →
Axial Therapeutics
HQ: United States
Website
- Description: Provider of gut-restricted and gut-selective small molecule therapeutics targeting the microbiome–gut–brain axis for neurological diseases. Offerings include AB-2004, a Phase 2 therapy for irritability associated with autism that adsorbs gut bacterial metabolites, and AX-5006 for Parkinson’s. Also offers a Microbial-Inspired Therapeutics discovery platform and early-stage programs in liver disease and oncology.
- Rationale: This competitor operates in a highly similar market segment with overlapping features.
- Company type: Private company
- Employees: ●●●●●
- Total funding raised: $●●●m
- Backers: ●●●●●●●●●●
- Acquisitions: ●●
View full Axial Therapeutics company profile →
Biocontrol
HQ: United Kingdom
Website
- Description: Provider of a novel system using biological agents to control bacterial infections by Pseudomonas aeruginosa, with proven efficacy and safety even where conventional antibiotics have failed.
- Rationale: This competitor operates in a highly similar market segment with overlapping features.
- Company type: Private company
- Employees: ●●●●●
- Total funding raised: $●●●m
- Backers: ●●●●●●●●●●
- Acquisitions: ●●
View full Biocontrol company profile →
BioCare Copenhagen
HQ: Denmark
Website
- Description: Provider of dietary supplements with microbial components for gastrointestinal problems, infections, and immune enhancement; offers medical nutrition, early life nutrition, pharma solutions, and nutrition improvement. Products include Humiome B2, supporting gut health by delivering a high percentage of vitamin B2 to the colon.
- Rationale: This competitor operates in a highly similar market segment with overlapping features.
- Company type: Private company
- Employees: ●●●●●
- Total funding raised: $●●●m
- Backers: ●●●●●●●●●●
- Acquisitions: ●●
View full BioCare Copenhagen company profile →
🔒
2.M&A buyers
2.1 Potential strategic acquirers in the sector
🔒
🔒
🔒
🔒
View all strategic buyers with complete profiles
Start Free Trial →
2.2 - Strategic buyer groups for 4D Pharma
🔒
Buyer group 1: ████████ ████████
●● companies
Description: ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████
Key Products: ████████, ████████, ████████, ████████
🔒
View all companies in this group
Request Free Trial Now →
🔒
Buyer group 2: ████████ ████████
●● companies
Description: ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████
Key Products: ████████, ████████, ████████, ████████
🔒
View all companies in this group
Request Free Trial Now →
🔒
Buyer group 3: ████████ ████████
●● companies
Description: ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████
Key Products: ████████, ████████, ████████, ████████
🔒
View all companies in this group
Request Free Trial Now →
🔓 Unlock all detailed buyer group breakdowns with complete company profiles
Start Free Trial →
3. Investors and private equity firms
3.1 - Buyout funds investing in similar companies to 4D Pharma
2.2 - Growth funds investing in similar companies to 4D Pharma
🔒
View all growth equity funds with complete profiles
Start Free Trial →
4 - Top valuation comps for 4D Pharma
4.2 - Public trading comparable groups for 4D Pharma
🔓 Unlock all public trading comparable groups with complete valuation data
Start Free Trial →